Viney highlights using two distinct types of mentors. Experienced founders slightly ahead in their journey provide practical operational fixes for issues like HR and space. In contrast, small confidential peer groups of identical seniority enable open brainstorming on recurring executive challenges.
Startup founders mistakenly believe early acquisitions require only minimum viable data. Big pharmaceutical acquirers examine assets with high scrutiny, making sloppy shortcuts risky. Generating robust, reproducible data packages from day one makes companies far more acquirable.
Scientific decision criteria are fundamentally similar between biotech startups and large pharma. The stark difference in decision speed is not analytical depth, but the bureaucracy of managing competing portfolio opportunities across multiple executive approval layers.
At inception, seed-funded biotechs face a dilemma: buying specialized laboratory equipment leaves no budget for talent, while hiring scientists without instrumentation leaves them idle. Shared incubators resolve this capital allocation trap entirely by providing plug-and-play infrastructure immediately.
Pandion discovered a modified IL-2 molecule that outperformed competitors despite violating their initial thesis of tissue-tethered modulation. Anchor decisions around patient impact rather than founder attachment to validate pursuing unexpected scientific deviations.
Acquisitions can induce genuine grief if a founder ties their identity solely to company ownership. Recognizing that deeper pharmaceutical capital ultimately accelerates clinical trial access for patients helps founders overcome the emotional shock of an exit.
Traditional protein engineering relies on slow, serial single-residue substitutions in wet labs to preserve stability. Machine learning models trained on evolutionary datasets can predict multiple coordinated amino acid changes simultaneously, cutting optimization rounds down from dozens to a handful.
Unlike antagonist therapeutics that rely on tight binding to block targets, agonist antibodies require lower affinity and rapid off-rates to signal continuously without receptor quenching. Applying machine learning based on natural ligands prevents teams from wasting cycles engineering inappropriate high affinities.
Founders regularly overlook articulating unmet need because it feels obvious to them. Successful life science fundraising requires framing the narrative externally: define the core problem, roadmap the solution, and state explicitly what de-risking milestone the capital unlocks.
Founders naturally risk drinking their own Kool-Aid by surrounding themselves with agreeable peers. Actively seeking harsh critics and skeptical investors surfaces hidden gaps, revealing whether a technical vulnerability is a fatal flaw or an experiment that can de-risk the program.
